Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2017
"The Report Juvenile Macular
Degeneration (Stargardt Disease) - Pipeline Review, H2 2017 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About
Juvenile
Macular Degeneration
Market
Global Markets Direct's latest
Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular
Degeneration (Stargardt Disease) - Pipeline Review, H2 2017, provides
an overview of the Juvenile Macular Degeneration (Stargardt Disease)
(Ophthalmology) pipeline landscape.
Juvenile macular degeneration is a series
of inherited eye disorders that affects children and young adults.
The most common form of juvenile macular degeneration is Stargardt
disease. Stargardt's disease is an inherited autosomal recessive
syndrome. Signs and symptoms include blurry or fuzzy vision, dark,
empty spots in the center of vision and difficulty reading or
performing detail work. Risk factors include arteriosclerosis,
hypercholesterolemia, smoking and hypertension.
Report Highlights
Global Markets Direct's Pharmaceutical
and Healthcare latest pipeline guide Juvenile Macular Degeneration
(Stargardt Disease) - Pipeline Review, H2 2017, provides
comprehensive information on the therapeutics under development for
Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology),
complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and
latest news and press releases.
The Juvenile Macular Degeneration
(Stargardt Disease) (Ophthalmology) pipeline guide also reviews of
key players involved in therapeutic development for Juvenile Macular
Degeneration (Stargardt Disease) and features dormant and
discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase II, Preclinical and Discovery stages
are 5, 10 and 1 respectively. Similarly, the Universities portfolio
in Preclinical stages comprises 2 molecules, respectively.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1305539
Juvenile Macular Degeneration (Stargardt
Disease) (Ophthalmology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The guide is built
using data and information sourced from Global Markets Directs
proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are
captured on a real time basis.
Note: Certain content / sections in the
pipeline guide may be removed or altered based on the availability
and relevance of data.
Scope
- The pipeline guide provides a snapshot
of the global therapeutic landscape of Juvenile Macular Degeneration
(Stargardt Disease) (Ophthalmology).
- The pipeline guide reviews pipeline
therapeutics for Juvenile Macular Degeneration (Stargardt Disease)
(Ophthalmology) by companies and universities/research institutes
based on information derived from company and industry-specific
sources.
- The pipeline guide covers pipeline
products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive
drug profiles for the pipeline products which comprise, product
description, descriptive licensing and collaboration details, R&D
brief, MoA & other developmental activities.
- The pipeline guide reviews key
companies involved in Juvenile Macular Degeneration (Stargardt
Disease) (Ophthalmology) therapeutics and enlists all their major and
minor projects.
- The pipeline guide evaluates Juvenile
Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics
based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
- The pipeline guide encapsulates all the
dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news
related to pipeline therapeutics for Juvenile Macular Degeneration
(Stargardt Disease) (Ophthalmology)
Reasons to buy
- Procure strategically important
competitor information, analysis, and insights to formulate effective
R&D strategies.
- Recognize emerging players with
potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
- Find and recognize significant and
varied types of therapeutics under development for Juvenile Macular
Degeneration (Stargardt Disease) (Ophthalmology).
- Classify potential new clients or
partners in the target demographic.
- Develop tactical initiatives by
understanding the focus areas of leading companies.
- Plan mergers and acquisitions
meritoriously by identifying key players and its most promising
pipeline therapeutics.
- Formulate corrective measures for
pipeline projects by understanding Juvenile Macular Degeneration
(Stargardt Disease) (Ophthalmology) pipeline depth and focus of
Indication therapeutics.
- Develop and design in-licensing and
out-licensing strategies by identifying prospective partners with the
most attractive projects to enhance and expand business potential and
scope.
- Adjust the therapeutic portfolio by
recognizing discontinued projects and understand from the know-how
what drove them from pipeline.
Table of
Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Juvenile Macular Degeneration (Stargardt
Disease) - Overview
Juvenile Macular Degeneration (Stargardt
Disease) - Therapeutics Development
Pipeline Overview
View
Sample PDF @
https://www.marketresearchreports.biz/reports/1305539/juvenile-macular-degeneration-stargardt-disease-pipeline-review-h2-2017-market-research-reports.pdf
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by
Universities/Institutes
Juvenile Macular Degeneration (Stargardt
Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Juvenile Macular Degeneration (Stargardt
Disease) - Companies Involved in Therapeutics Development
Acucela Inc
Alkeus Pharmaceuticals Inc
Astellas Pharma Inc
Copernicus Therapeutics Inc
Grupo Ferrer Internacional SA
Iris Pharma
Nemus Bioscience Inc
Ophthotech Corp
ProQR Therapeutics NV
Sanofi
Juvenile Macular Degeneration (Stargardt
Disease) - Drug Profiles
ALK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
echothiophate iodide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emixustat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FAB-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy 1 to Activate ABCA4 for
Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ABCA4 for
Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBS-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Activate ABCA4 for
Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-1011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ramiprilat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme for Age Related
Macular Degeneration and Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-422459 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
soraprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Ophthalmic
Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1305539
About us
MarketResearchReports.biz is the most
comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment